 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «1234567891011» |
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Trial completion, Enrollment change: SHEAR-STENT: Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels (clinicaltrials.gov) - Oct 15, 2021
P=N/A, N=81, Completed, Sponsor: Emory University
Recruiting --> Completed | N=126 --> 81
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date: RESOLUTE ONYX China Single Arm Study (clinicaltrials.gov) - Oct 14, 2021
P=N/A, N=591, Active, not recruiting, Sponsor: Medtronic Vascular
Recruiting --> Completed | N=126 --> 81 Trial completion date: Dec 2024 --> Oct 2025
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date: RESOLUTE ONYX China RCT Study (clinicaltrials.gov) - Oct 14, 2021
P=N/A, N=550, Active, not recruiting, Sponsor: Medtronic Vascular
Trial completion date: Dec 2024 --> Oct 2025 Trial completion date: Dec 2024 --> Sep 2025
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date: ONYX PAS: RESOLUTE ONYX Post-Approval Study (clinicaltrials.gov) - Oct 11, 2021
P=N/A, N=416, Active, not recruiting, Sponsor: Medtronic Vascular
Trial completion date: Dec 2024 --> Sep 2025 Trial completion date: Aug 2023 --> Sep 2022
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Comparative Safety of Bioabsorbable Polymer Everolimus-Eluting, Durable Polymer Everolimus-Eluting, and Durable Polymer Zotarolimus-Eluting Stents in Contemporary Clinical Practice. (Pubmed Central) - Sep 29, 2021
Our data suggest similar risk-adjusted in-hospital outcomes among drug-eluting stent platforms commonly used in clinical practice. The absence of a difference in 2-year mortality between BP-EES, DP-EES, and DP-ZES suggests that stent choice decisions could be made based on other factors, including durability, availability, and cost.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
nice work ! Was it a resolute onyx stent ? (Twitter) - Sep 27, 2021
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic, NN1213 / Novo Nordisk
Trial primary completion date, Surgery: FAME 3: A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease (clinicaltrials.gov) - Sep 21, 2021
P4, N=1500, Active, not recruiting, Sponsor: Stanford University
The absence of a difference in 2-year mortality between BP-EES, DP-EES, and DP-ZES suggests that stent choice decisions could be made based on other factors, including durability, availability, and cost. Trial primary completion date: Dec 2020 --> Dec 2021
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Incidence and predictors of target lesion failure in patients with lesions in small vessels undergoing PCI with contemporary drug-eluting stents: Insights from the BIONICS study. (Pubmed Central) - Sep 15, 2021
1910 patients were randomized to treatment with the EluNIR™ ridaforolimus-eluting stent (RES) or Resolute™ zotarolimus-eluting stent (ZES)...2 year TLF rates were similar in the RES and ZES patient groups (P 0.86). In conclusion, patients undergoing PCI in small vessels have significantly worse outcomes despite the use of contemporary stents.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion: Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI (clinicaltrials.gov) - Sep 1, 2021
P=N/A, N=932, Completed, Sponsor: Keimyung University Dongsan Medical Center
In conclusion, patients undergoing PCI in small vessels have significantly worse outcomes despite the use of contemporary stents. Active, not recruiting --> Completed
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Preclinical, Journal: Radiopacity of Coronary Stents, an In Vitro Comparative Study. (Pubmed Central) - Aug 26, 2021
This study highlighted significant differences in the radiopacity of coronary stents deployed in a bench test model. The strut thickness and the presence of platinum increased the radiopacity.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Review, Journal: Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients: LEADERS-FREE and ONYX ONE. (Pubmed Central) - Aug 20, 2021
The risk of late stent thrombosis appears less with newer-generation stents, and polymer-free drug-coated stents (DCS) may improve clinical efficacy relative to a bare metal stent without the potential long-term hazards associated with a durable polymer. Based on the outcomes of recent clinical trials, risk stratification to identify high bleeding risk patients and appropriate selection of a polymer-free drug-coated or durable-polymer zotarolimus-eluting stent may optimize clinical outcomes in patients who require an abbreviated DAPT regimen.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Thanks @aayshacader It was a Resolute Onyx (Twitter) - Aug 13, 2021
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: A randomized comparison of Coronary Stents according to Short or Prolonged durations of Dual Antiplatelet Therapy in patients with Acute Coronary Syndromes: a pre-specified analysis of the SMART-DATE trial. (Pubmed Central) - Aug 12, 2021
Based on the outcomes of recent clinical trials, risk stratification to identify high bleeding risk patients and appropriate selection of a polymer-free drug-coated or durable-polymer zotarolimus-eluting stent may optimize clinical outcomes in patients who require an abbreviated DAPT regimen. The risk of a composite of cardiac death, myocardial infarction, or stent thrombosis was not significantly different between patients receiving BP-BES versus DP-EES or DP-ZES across a short or prolonged duration of DAPT after ACS.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Clinical data, Journal: Three-year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus-eluting stent and the durable biocompatible polymer Resolute Integrity zotarolimus-eluting stent: A randomized controlled trial. (Pubmed Central) - Aug 11, 2021
This study confirms long-term safety and efficacy of the two stents. We found a trend for lower target lesion failure with O-SES compared to R-ZES, although statistically insignificant.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Journal: Acute thrombogenicity of fluoropolymer coated stents versus competitive drug-eluting stents under single antiplatelet therapy. (Pubmed Central) - Aug 6, 2021
We found a trend for lower target lesion failure with O-SES compared to R-ZES, although statistically insignificant. These results suggest FP-EES may have particular advantage for short-term DAPT compared to other DESs.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Journal: Difference of vascular healing between bioabsorbable-polymer and durable-polymer new generation drug-eluting stents: an optical coherence tomographic analysis. (Pubmed Central) - Jul 7, 2021
The percentage of uncovered struts and malapposed struts were significantly lower (7.2 ± 8.9 vs. 15.0 ± 17.1%, p = 0.01, 0.9 ± 1.7 vs. 2.7 ± 5.2%, p = 0.03) and the mean NIH thickness was significantly thicker in BP group than DP group (112 ± 54 vs. 83 ± 31 µm, p < 0.01). The present OCT study demonstrated that uncovered struts and malapposed struts were less common with bioabsorbable-polymer stents than with durable-polymer stents.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Journal: Comparison of Acute Thrombogenicity and Albumin Adsorption in Three Different Durable Polymer Coronary Drug-Eluting Stents. (Pubmed Central) - Jun 30, 2021
The present OCT study demonstrated that uncovered struts and malapposed struts were less common with bioabsorbable-polymer stents than with durable-polymer stents. These results suggest that thromboresistance and albumin retention vary by polymer type and that these differences might result in different suitability for short-term dual antiplatelet therapy.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Clinical, Journal: Three contemporary thin-strut drug-eluting stents implanted in severely calcified coronary lesions of participants in a randomized all-comers trial. (Pubmed Central) - Jun 30, 2021
P=N/A
These results suggest that thromboresistance and albumin retention vary by polymer type and that these differences might result in different suitability for short-term dual antiplatelet therapy. In BIO-RESORT participants with severely calcified target lesions, treatment with EES was associated with a lower 2-year target vessel revascularization rate than treatment with ZES.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
New trial: Safety and Efficacy of Drug-Coated Balloon for De-novo Lesions in Patients With Acute Coronary Syndromes (DCB-ACS) (clinicaltrials.gov) - Jun 24, 2021
P=N/A, N=212, Recruiting, Sponsor: Harbin Medical University
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: A Case of Wellens Syndrome in a 30-Year-Old Woman From Sub-Saharan Africa: A Perplexing Clinical Entity With Invaluable Lessons. (Pubmed Central) - Jun 23, 2021
Subsequently, angioplasty was performed successfully with a resolute integrity stent, and TIMI III flow was achieved. To conclude, despite its relative frequency, physicians' awareness of Wellens syndrome pathognomonic ECG features is of paramount importance to curb its attributable morbidity and mortality.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. (Pubmed Central) - Jun 22, 2021
P=N/A
Among HBR patients who were event free before DAPT discontinuation at 1 month, favorable safety and effectiveness through 1 year support treatment with Resolute Onyx drug-eluting stents as part of an individualized strategy for shortened DAPT duration following percutaneous coronary intervention. Registration: URL: https://www.clinicaltrials.gov; Unique identifier NCT03647475.
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Enrollment open: TARGET-IV_NA: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial (clinicaltrials.gov) - Jun 15, 2021
P=N/A, N=1616, Recruiting, Sponsor: Shanghai MicroPort Medical (Group) Co., Ltd.
Registration: URL: https://www.clinicaltrials.gov; Unique identifier NCT03647475. Not yet recruiting --> Recruiting
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: Thromboresistance and endothelial healing in polymer-coated versus polymer-free drug-eluting stents: Implications for short-term dual anti-platelet therapy. (Pubmed Central) - May 29, 2021
Thromboresistance was superior to PF-BES and healing was equivalent to PF-BES in this pre-clinical study. Onyx-DES might provide advantages when considering short-term DAPT especially in patients at high risk of bleeding.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Resolute Onyx 4.5x30mm, POT with a 5.0x8mm NC balloon. LM reference diameter approximately 5.5mm. Was ready to use a 6.0 compliant balloon, but after POT with 5.0 NC at 20atm thought it wasn’t necessary since expansion and apposition was ok (Twitter) - May 15, 2021
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
Journal: Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. (Pubmed Central) - May 15, 2021
Severe calcification, especially surface calcified area is an independent predictor of uncovered struts and delayed healing after newer-generation DES implantation. These data expand of knowledge of the vascular responses of stenting of calcified arteries and suggests further understand of how best to deal with calcification in patients undergoing PCI.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Patient-specific modelling of stent overlap: Lumen gain, tissue damage and in-stent restenosis. (Pubmed Central) - May 15, 2021
Abaqus CAE was used to create the models for Resolute Integrity™ drug-eluting stents and tri-folded expansion balloons...Also, non-overlapping stents induced more tissue damage and higher rate of in-stent restenosis than overlapping stents. With respect to long-term clinical outcomes, the study recommended the use of a single stent where possible or multiple stents with minimal overlaps to treat long or angulated lesions.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
New trial: DEBORA: Drug-eluting Balloon Versus Drug-eluting Stent for High Bleeding Risk Angioplasty (clinicaltrials.gov) - May 12, 2021
P=N/A, N=120, Recruiting, Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Synergy Megatron and 4.5/5 Resolute Onyx can be expanded up to 6 mm. That should take care of almost any coronary except for #aneurysms. #cardiotwitter (Twitter) - May 10, 2021
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion: A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear) (clinicaltrials.gov) - May 6, 2021
P=N/A, N=752, Completed, Sponsor: Medtronic Vascular
With respect to long-term clinical outcomes, the study recommended the use of a single stent where possible or multiple stents with minimal overlaps to treat long or angulated lesions. Active, not recruiting --> Completed
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: Times up to demonstrate a difference is current DES platforms. (Pubmed Central) - May 1, 2021
The Orsiro DES has both a bioresorbable polymer and ultra thin struts and has the potential to improve the safety of DES. In this all comers trial, 3 year outcomes with Orsiro DES were similar to the durable polymer zotarolimus eluting stent.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date, Trial primary completion date: Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) (clinicaltrials.gov) - Apr 28, 2021
P=N/A, N=2400, Recruiting, Sponsor: Elixir Medical Corporation
In this all comers trial, 3 year outcomes with Orsiro DES were similar to the durable polymer zotarolimus eluting stent. Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2022 --> Dec 2022
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date: RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort) (clinicaltrials.gov) - Apr 22, 2021
P=N/A, N=205, Active, not recruiting, Sponsor: Medtronic Vascular
Trial completion date: Sep 2026 --> Dec 2026 | Trial primary completion date: Sep 2022 --> Dec 2022 Trial completion date: Jan 2023 --> Apr 2023
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date: ONYX PAS: RESOLUTE ONYX Post-Approval Study (clinicaltrials.gov) - Apr 22, 2021
P=N/A, N=416, Active, not recruiting, Sponsor: Medtronic Vascular
Trial completion date: Jan 2023 --> Apr 2023 Trial completion date: Feb 2021 --> Aug 2023
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
I like this slide, although it’s very difficult to make any meaningful differences on currently available DES platforms, they all excellent but I believe there are still few nuances to each stent,I like Resolute Onyx b/c it has 2 mm diameter, also shows better on fluoroscopy. (Twitter) - Apr 15, 2021
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Clinical data, Journal: Comparison of the Major Clinical Outcomes for the Use of Endeavor® and Resolute Integrity® Zotarolimus-Eluting Stents During a Three-Year Follow-up. (Pubmed Central) - Apr 14, 2021
Although I-ZES utilizes a more advanced stent platform, stent design, and polymer system than E-ZES, both the ZESs showed comparable efficacy and safety during the 3-year follow-up period in this single-center, all-comers registry. However, further large-scaled, randomized, well-controlled trials with long-term follow-up are needed to verify these results.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Procedural, clinical, and health status outcomes in chronic total coronary occlusion revascularization: Results from the PERSPECTIVE study. (Pubmed Central) - Apr 7, 2021
However, further large-scaled, randomized, well-controlled trials with long-term follow-up are needed to verify these results. Favorable procedural success, health status improvements and late-term clinical outcomes inform the relative risks and benefits of CTO PCI when performed in a clinically indicated, complex patient population representative of those treated in clinical practice.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Journal: Five-Year Comparative Efficacy of Everolimus-Eluting vs. Resolute Zotarolimus-Eluting Stents in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. (Pubmed Central) - Apr 7, 2021
In ACS, a greater long-term clinical efficacy with EES vs. R-ZES was observed. This difference became significant after the first year of the ACS episode and persisted thereafter.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
New trial: Efficacy and Safety of ZotaRolimus-Eluting Coronary Stent System In Patients With Long Coronary Artery Disease (clinicaltrials.gov) - Apr 1, 2021
P, N=2000, Recruiting, Sponsor: Chonnam National University Hospital
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Journal: Staged Repair of Van Praagh Truncus Type A3. (Pubmed Central) - Mar 31, 2021
The pulmonary arteries grew and at four months of age had an acceptable McGoon ratio and Nakata index. The patient then underwent repair which included unifocalization of the branch pulmonary arteries, closure of the ventricular septal defect, and placement of a right ventricle-to-pulmonary artery homograft conduit.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Clinical data, Journal: Five-year clinical outcomes for the Resolute zotarolimus-eluting stent in total coronary occlusions. (Pubmed Central) - Mar 25, 2021
The patient then underwent repair which included unifocalization of the branch pulmonary arteries, closure of the ventricular septal defect, and placement of a right ventricle-to-pulmonary artery homograft conduit. In this large population of patients who had R-ZES implanted, five-year clinical outcomes were similar whether or not the stents were implanted in total occlusions.
- || Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical, Clinical data, Journal, Monotherapy: Comparison of the 9-Month Intrastent Condition and 30-Month Clinical Outcomes After Resolute Zotarolimus-Eluting Stent Implantation Between Standard-Duration and 1-Month Dual Antiplatelet Therapy Followed by Prasugrel Monotherapy. (Pubmed Central) - Mar 12, 2021
In this large population of patients who had R-ZES implanted, five-year clinical outcomes were similar whether or not the stents were implanted in total occlusions. In conclusion, 1M DAPT followed by prasugrel monotherapy after second-generation drug-eluting stent implantation was not inferior to standard-duration DAPT in terms of intrastent thrombus formation and composite adverse events.
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
New trial: Disco-9: Registry of RESOLUTE-ONYX (clinicaltrials.gov) - Mar 7, 2021
P, N=307, Completed, Sponsor: Fundaci
- ||| Resolute ZES (zotarolimus-eluting stent) / Medtronic
Clinical: Comparative Safety of Bioabsorbable Polymer Everolimus-Eluting, Durable Polymer Everolimus-Eluting, and Durable Polymer Zotarolimus-Eluting Stents in Contemporary Clinical Practice https://t.co/Tz4qjUGZze (Twitter) - Feb 26, 2021
- | Resolute ZES (zotarolimus-eluting stent) / Medtronic
Trial completion date, Trial primary completion date: Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI (clinicaltrials.gov) - Feb 21, 2021
P=N/A, N=932, Active, not recruiting, Sponsor: Keimyung University Dongsan Medical Center
In conclusion, 1M DAPT followed by prasugrel monotherapy after second-generation drug-eluting stent implantation was not inferior to standard-duration DAPT in terms of intrastent thrombus formation and composite adverse events. Trial completion date: Dec 2020 --> Jun 2021 | Trial primary completion date: Dec 2020 --> Jun 2021
- Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
[VIRTUAL] RETROSPECTIVE OBSERVATION STUDY TO COMPARE THE EFFICACY AND SAFETY BETWEEN TWO ULTRATHIN DRUG-ELUTING STENTS - GENOSS DES VS. ORSIRO (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_5365;
In a single-center prospective registry with unrestricted use of the Genoss DES stent and Orsiro stent, these two ultrathin DES showed comparable efficacy during the 2-year follow-up. However, the safety regarding stent thrombosis should be confirmed in a large randomized controlled trial.
- Resolute ZES (zotarolimus-eluting stent) / Medtronic
[VIRTUAL] THREE-YEAR OUTCOME OF ALL-COMER PATIENTS TREATED WITH RESOLUTE ONYX ZOTAROLIMUS-ELUTING VERSUS ORSIRO SIROLIMUS-ELUTING STENTS IN THE RANDOMIZED BIONYX TRIAL (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_5131;
P=N/A
RO-ZES versus O-SES showed no difference in the main endpoint of safety and efficacy at 3-years. A lower rate of all-cause mortality in the RO-ZES group may most likely be a play of chance, yet long-term follow-up is of interest.
- Resolute ZES (zotarolimus-eluting stent) / Medtronic, Xience (everolimus-eluting stent) / Abbott
[VIRTUAL] A HYBRID CORONARY RE-VASCULARIZATION FOR MANAGING IN-STENT RESTENOSIS (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_4231;
It combines strengths from both PCI and traditional CABG surgery. Only 0.5% of CABG surgeries are HCR in the USA.
- Resolute ZES (zotarolimus-eluting stent) / Medtronic
[VIRTUAL] “ROTATRIPSY”-COMBINATION OF ROTATIONAL ATHERECTOMY AND INTRAVASCULAR LITHOTRIPSY FOR TREATMENT OF UNDILATABLE SEVERELY CALCIFIED LESIONS IN CHRONIC TOTAL OCCLUSION OF RIGHT CORONARY ARTERY () - Feb 17, 2021 - Abstract #ACC2021ACC_2807;
3.0 X 34 mm Resolute Onyx stent was deployed with adequate post dilatation . Post stenting OCT showed well apposed stent, no evidence of malapposition or edge dissection with Minimum Lumen Area (MLA) of 7.37 mm2 with diameter of 3.06 mm at distal part of stent and 3.69 mm diameter at proximal part of stent with excellent end result.
- Resolute ZES (zotarolimus-eluting stent) / Medtronic
[VIRTUAL] ONE YEAR CLINICAL OUTCOMES IN PATIENTS WITH CORONARY BIFURCATION LESIONS: RESULTS FROM THE RESOLUTE ONYX BIFURCATION STUDY (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_1630;
A provisional stent approach to coronary bifurcation lesions using the Resolute Onyx DES was associated with low rates of TVF at 1 year compared to historical controls with infrequent peri-procedural and non-procedural MI. These results support the safety and effectiveness of Resolute Onyx in this complex lesion subset.
- Resolute ZES (zotarolimus-eluting stent) / Medtronic
[VIRTUAL] COVID-19 TRIGGERED ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (eAbstract site) - Feb 17, 2021 - Abstract #ACC2021ACC_166;
Our case aims to express the possible cardiovascular complications of COVID-19 in a patient without any risk factors or history predisposing to cardiac disease, making the presentation even more striking. Current treatment regimens for COVID-19 now includes anticoagulation in order to prevent hypercoagulable sequalae and decrease patient morbidity and mortality.